GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) agreed to acquire Intelerad for $2.3 billion in cash, aiming to create a cloud-first, AI-enabled enterprise imaging platform across inpatient and outpatient settings.
The deal is expected to close in H1 2026, accelerate GE HealthCare’s SaaS and recurring-revenue mix, and support the company’s goal to triple cloud-enabled offerings by 2028.
Intelerad is forecast to deliver ~$270 million revenue in the first full year (≈90% recurring) and an adjusted EBITDA margin >30%; GEHC expects immediate top-line and EBIT margin accretion, short-term slight EPS dilution due to financing, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) announced that Cardiovascular Associates of America (CVAUSA) plans to expand use of FDA‑approved PET radiotracer Flyrcado (flurpiridaz F 18) across ~25 sites after a successful two‑week, 21‑patient pilot at Cardiovascular Medicine in Davenport, Iowa.
The network performs about 85,000 cardiac PET procedures annually, and GE highlighted new distribution support with CDL Nuclear Technologies and inclusion of flurpiridaz F 18 in a co‑published international procedure standard for cardiac PET MPI.
GE HealthCare (Nasdaq: GEHC) management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 am GMT / 4:30 am ET / 3:30 am CT.
CFO Jay Saccaro will discuss business strategy and growth opportunities and will address recent questions about a competitor’s FDA approval of an X-ray contrast product; GE HealthCare does not expect that approval to have a material impact on its Pharmaceutical Diagnostics business. A live webcast will be available on the company investor website at the listed date and time.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 am GMT (4:30 am ET/3:30 am CT).
A live webcast will be available via the company's investor events page at https://investor.gehealthcare.com/news-events/events on the listed date and time.
GE HealthCare (Nasdaq: GEHC) reported third-quarter 2025 results for the period ended September 30, 2025. Revenues were $5.1 billion, up 6% reported and 4% organic year‑over‑year, with total company orders +6% organic and a book‑to‑bill of 1.06. Net income attributable to GE HealthCare was $446 million; diluted EPS was $0.98 and Adjusted EPS was $1.07. Adjusted EBIT margin was 14.8% and free cash flow was $483 million. The company raised the lower end of full‑year 2025 Adjusted EPS guidance to a range of $4.51 to $4.63 and reaffirmed other metrics while noting approximately $265 million of tariff impact to Adjusted EBIT and $0.45 to Adjusted EPS.
GE HealthCare (Nasdaq: GEHC) announced CE mark clearance for its new Carevance patient monitor on October 21, 2025, enabling initial commercial access in Europe.
Carevance adds Cardiac Output Insights — a non-invasive, on-device hemodynamic view that provides real-time graphical support for perioperative hypotension management without extra hardware or invasive catheters. The platform uses proven algorithms and validated vital-sign parameters and includes the EK-Pro algorithm, which the company says can reduce false ECG alarms by up to 92%. Carevance will be showcased at ESICM in Munich, Oct 25-29, 2025.
GE HealthCare (Nasdaq: GEHC) on October 20, 2025 announced collaborations with The Queen’s Health Systems and Duke Health to co‑develop a new AI‑driven, cloud‑first hospital operations application in its CareIntellect family.
The solution will use predictive analytics to recommend actions across bed demand, staffing, and equipment, drawing on insights from ~500 hospitals (55,000 beds) that use Command Center. Queen’s cited measurable results: 22.2% jump in transfer admissions, 41.2% ED length‑of‑stay reduction, 1.07 day overall LOS drop, and $20M estimated first‑year savings.
GE HealthCare (Nasdaq: GEHC) launched CareIntellect for Perinatal on October 14, 2025, a cloud-first SaaS application built to deliver real-time clinical insights that streamline maternal and fetal care workflows.
The solution integrates uterine activity, blood pressure, fetal heart rate, and maternal SpO2 into a unified chronological view, supports remote monitoring, and runs on a common AWS cloud infrastructure shared across CareIntellect applications for faster deployment, single-sign on, centralized access management, and seamless updates.
Development included clinician input from 29 physicians and 85 nurses across 12 hospitals via a collaboration with HCA Healthcare. GE HealthCare will showcase the product at HLTH 2025 (Oct 19–22).
GE HealthCare (Nasdaq: GEHC) presented University of Michigan findings at ANESTHESIOLOGY 2025 (Oct 10–14) showing End-tidal Control software was associated with lower anesthetic use and emissions in real-world care. The retrospective analysis covered 14,730 adult general anesthesia cases, with End-tidal Control used in 50.5% of cases and active for 82.1% of the maintenance phase. Preliminary results reported reductions of greater than 35% in fresh gas flow, sevoflurane utilization and CO2 emissions during maintenance. The release notes prior GE funding of the study and references additional supporting abstracts and a separate Missouri study with similar lower-flow and cost findings.
GE HealthCare (Nasdaq: GEHC) unveiled Carestation 850, a next-generation anesthesia delivery system with FDA 510(k) pending, following a recent CE mark and approvals in Australia and New Zealand. The system targets perioperative precision with an ergonomic, space-conscious design, continuously optimized algorithms, a widescreen display, refill-while-in-use vaporization and customizable applications for patients from neonates to the elderly. GE HealthCare will showcase Carestation 850 at ANESTHESIOLOGY 2025 (Oct 10–14) at booth #1314. The release cites workforce strain—an estimated 68% of anesthesia professionals at high burnout risk and a projected anesthesiologist shortage of 12,500 by 2033—as drivers for technology adoption and efficiency improvements.